Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
42.84
-0.85 (-1.95%)
Nov 21, 2024, 10:43 AM EST - Market open
Mirum Pharmaceuticals Revenue
Mirum Pharmaceuticals had revenue of $90.38M in the quarter ending September 30, 2024, with 89.37% growth. This brings the company's revenue in the last twelve months to $307.03M, up 112.14% year-over-year. In the year 2023, Mirum Pharmaceuticals had annual revenue of $186.37M with 141.85% growth.
Revenue (ttm)
$307.03M
Revenue Growth
+112.14%
P/S Ratio
6.71
Revenue / Employee
$1,162,985
Employees
264
Market Cap
2.05B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Astrana Health | 1.72B |
Addus HomeCare | 1.13B |
Evotec SE | 866.67M |
Supernus Pharmaceuticals | 651.97M |
NeoGenomics | 644.12M |
GeneDx Holdings | 267.23M |
Ligand Pharmaceuticals | 152.42M |
Wave Life Sciences | 53.61M |
MIRM News
- 7 days ago - Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD's The Liver Meeting - Business Wire
- 8 days ago - Mirum Pharmaceuticals, Inc. (MIRM) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
- 12 days ago - Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 13 days ago - Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire
- 16 days ago - Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 - Business Wire
- 21 days ago - Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting - Business Wire
- 6 weeks ago - Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis - Business Wire